Wockhardt’s indirect subsidiary, CP Pharmaceuticals, UK received USFDA warning letter for GMP violation
Posted on29 Nov 2016
Tags483 OBSERVATION, 483 observations, fda 483 observation, FORM 483, form 483 observation, USFDA warning letter
Comments0
Wockhardt’s indirect subsidiary, CP Pharmaceuticals, UK received USFDA warning letter for GMP violoation Wockhardt Ltd has received a warning letter from the... Read More
FDA Approves NDA For Xultophy 100/3.6 for Type 2 Diabetes
The FDA has approved the new drug application for Novo Nordisk’s Xultophy 100/3.6 as an adjunct to diet and exercise in adults... Read More
Sanofi Pasteur’s pediatric vaccine Hexaxim launch in India
Posted on25 Nov 2016
Comments0
Sanofi Pasteur, the vaccines global business unit of Sanofi, has launched India’s first innovative ready-to-use fully liquid 6-in-1 vaccine – Hexaxim. The... Read More
Sun Pharma received 483 observation for Mohali Plant
Posted on25 Nov 2016
Comments0
Reason for 483 observation issued: Deviation from manufacturing standard About Plant: The Mohali facility, which belonged to Ranbaxy Laboratories Ltd, has been... Read More
Allergan’s acquisition of Chase Pharmaceuticals – Cipla divests its 16.7% stake in Chase Pharmaceuticals Corp
Allergan plc announced acquisition of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders... Read More
Sun Pharma’s Strategic Expansion in Russia: To acquire majority stake in Russia’s Biosintez
Sun Pharmaceutical Industries Ltd has agreed to acquire an 85.1% stake in Russian drugmaker JSC Biosintez as part of its strategy to... Read More
GSK files US regulatory submission for triple COPD therapy approval
Posted on22 Nov 2016
Comments0
GlaxoSmithKline and Innoviva have filed for approval in the US of a new once-daily, triple combination therapy for maintenance treatment of patients... Read More
The U.S. FDA approves Soliqua 100/33 for the treatment of adults with type 2 diabetes
Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved once-daily Soliqua 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL... Read More
Insight of Novartis’s acquisition of Selexys Pharmaceuticals Corporation
Novartis announced that it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders.... Read More
Battle of Pharmaceutical Trademark: GlaxoSmithKline wins ‘GSK’ trademark battle in India
GlaxoSmithKline wins in a three-years long court battle over its trademark rights with a Hyderabad company which used the same acronym. What... Read More